Winnonlin phoenix version 6.2.1 or higher

Whole blood and plasma TRA data as well as niraparib plasma concentrations were used to determine the maximum observed plasma concentration (C_max), time to reach maximum plasma concentration following drug ingestion (t_max), the area under the plasma concentration-time curve from time zero to time of last measurable concentration (AUC_0-last), and if the data allowed, area under the plasma concentration-time curve from time zero to infinity (AUC_0-inf), apparent volume of distribution during terminal phase V_d/F, apparent total clearance of the drug from plasma after oral administration (CL/F), and the terminal phase half-life (t_1/2)_. Analysis was done by a non-compartmental method using WinNonlin Phoenix Version 6.2.1 or higher (Pharsight Corporation, St. Louis, Missouri, USA).

Plasma niraparib and radioactivity concentrations were used to determine the following pharmacokinetic parameters: C_max; time to reach C_max (t_max); AUC from time 0 to the last quantifiable concentration (AUC_0–last; calculated using the linear-up/log-down trapezoidal rule, with the linear trapezoidal rule applied up to the t_max and the log-linear trapezoidal rule applied after the t_max); AUC from time 0 to infinity (AUC_0–inf; calculated using the linear-up/log-down trapezoidal rule); volume of distribution (V_d); apparent oral volume of distribution (V_d/F); clearance (CL); apparent oral clearance (CL/F); and half-life (t_½). Analyses were done by a noncompartmental method using WinNonlin Phoenix Version 6.2.1 or higher (Pharsight Corporation, St. Louis, Missouri, USA). All calculations for final analysis were based on actual sampling times.